Research Reports | Market Assessment
March 2022

Idiopathic Pulmonary Fibrosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

*NOTE: the brochure was already reviewed by an editor*

MARKET OUTLOOK

Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in the lungs. While the prognosis for patients diagnosed with IPF is poor (survival of three to five years after diagnosis, in most cases), various therapies can relieve symptoms, prevent further lung scarring, and improve patients’ quality of life. Different drug classes are used to target the respective physiological mechanisms. Tyrosine kinase inhibitors (nintedanib [Boehringer Ingelheim’s Ofev]), for example, blocks the action of enzymes that cause fibrosis, while antifibrotic agents such as pirfenidone (Roche / Genentech’s Esbriet) reduce lung fibrosis by downregulating growth factor production. This analysis of patient-level claims data provides insights into the dynamics of the IPF treatment landscape.

QUESTIONS ANSWERED

•What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IPF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IPF patients?
•How have nintedanib (Boehringer Ingelheim’s Ofev) and pirfenidone (Roche / Genentech’s Esbriet) been integrated into the treatment algorithm, and what are their sources of business?
•What percentage of IPF patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
•What percentage of IPF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
•What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Markets covered: United States

Key drugs: Azathioprine, benralizumab, nintedanib, pirfenidone, sildenafil

  added by Sabah on Mar 28

Table of contents

  • Idiopathic Pulmonary Fibrosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms CDA Idiopathic Pulmonary Fibrosis US April 2022
    • Treatment Algorithms CDA Idiopathic Pulmonary Fibrosis US 2022 Dashboard
Muthana Sweis
Muthana Sweis

Muthana Sweis, M.P.H., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has authored content for indications such as emerging vaccines, essential thrombocythemia, idiopathic pulmonary fibrosis, and myelodysplastic syndromes. He earned his master’s degree in public health from DePaul University.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports